Payment overview · 2025
General Payments
$618.95
30 reported records · 9 companies
Healthcare provider profile · identity verified
Erin L Green, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · JONESBORO, AR · NPI 1043660194
Verified facts
What the public records show
CMS Open Payments records show Erin L Green, APRN received $618.95 in general payments during 2025 across 30 reported records.
Lilly USA, LLC accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $230.94 | 37.3% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $147.16 | 23.8% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $128.42 | 20.8% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $27.18 | 4.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.73 | 4.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.50 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.12 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.95 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.95 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $618.95 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $230.94 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $147.16 | 9 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $140.59 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $128.42 | 6 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 190 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 70 |
| Lisinopril | Lisinopril | 166 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 47 |
| Gabapentin | Gabapentin | 136 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 132 | 49 |
| Tramadol Hcl | Tramadol Hcl | 125 | 45 |
| Omeprazole | Omeprazole | 120 | 48 |
| Donepezil Hcl | Donepezil Hcl | 115 | 42 |
| Potassium Chloride | Potassium Chloride | 114 | 42 |
| Furosemide | Furosemide | 111 | 47 |
| Metformin Hcl | Metformin Hcl | 111 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 36 |
| Trazodone Hcl | Trazodone Hcl | 103 | 35 |
| Memantine Hcl | Memantine Hcl | 97 | 33 |
| Losartan Potassium | Losartan Potassium | 95 | 38 |
| Buspirone Hcl | Buspirone Hcl | 93 | 32 |
| Clonazepam | Clonazepam | 91 | 28 |
| Famotidine | Famotidine | 88 | 33 |
| Meloxicam | Meloxicam | 83 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 31 |
| Pregabalin | Pregabalin | 74 | 25 |
| Methylprednisolone | Methylprednisolone | 67 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 29 |
| Mirtazapine | Mirtazapine | 64 | 25 |
| Carvedilol | Carvedilol | 59 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 19 |
| Alprazolam | Alprazolam | 54 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 28 |
| Sertraline Hcl | Sertraline Hcl | 48 | 23 |
| Cefdinir | Cefdinir | 42 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 36 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 13 |
| Montelukast Sodium | Montelukast Sodium | 38 | 15 |
| Eliquis | Apixaban | 37 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Prednisone | Prednisone | 37 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 13 |
| Lorazepam | Lorazepam | 36 | 12 |
| Simvastatin | Simvastatin | 35 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Alendronate Sodium | Alendronate Sodium | 33 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 14 |
| Bupropion Xl | Bupropion Hcl | 30 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 21 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Glipizide | Glipizide | 29 | 14 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 25 | 23 |
| Nystatin | Nystatin | 25 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Mupirocin | Mupirocin | 19 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $618.95 · 30 records | Lilly USA, LLC | AMYVID, EVENITY, KISUNLA, Leqembi, REXULTI, SAPIEN 3 Ultra RESILIA, SYNCHROMEDII, The Cologuard Plus Collection Kit, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error